← Back to Search
Site-Specific Symptom Management: Palliative Radiotherapy For Advanced And Metastatic Lung Cancer
R. Rhome, K. Dharmarajan
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Palliative radiation can be useful in numerous clinical scenarios with respect to primary or metastatic thoracic tumors. Extensive stage small cell lung cancer (SCLC) and locally advanced, unresectable nonsmall cell lung cancer (NSCLC) are the most common causes of symptoms that can be managed even in the setting of incurable underlying disease. Dyspnea, pain, hemoptysis, and superior vena cava syndrome are some manifestations of thoracic tumor invasion that compromise quality of life and survival. Multiple trials have been conducted to assess symptom relief and survival, with some conflicting evidence. Palliation of symptoms is reasonably achieved in most of these studies, and some show benefits in survival or tumor regression. Various fractionation schemas have been studied to determine the optimal symptom control. Metaanalyses have attempted to identify subsets of patients that benefit more, with performance status emerging as consistent predictor of benefit. Patient selection remains crucial to determining the risk–benefit ratio of any regimen.
This paper references
Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.
Xiong Wei (2008)
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer.
R. Stout (2000)
Palliative endobronchial brachytherapy for non-small cell lung cancer.
L. Reveiz (2012)
Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus.
N. P. Rowell (2001)
Superior Vena Cava Syndrome with Malignant Causes
L. Wilson (2007)
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.
Kyle E. Rusthoven (2009)
Immediate side effects of large fraction radiotherapy.
S. Devereux (1997)
A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)
E. Senkus-Konefka (2005)
Superior Vena Cava Syndrome—A Proposed Classification System and Algorithm for Management
J. Yu (2008)
Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.
F. Macbeth (1996)
Palliative endobronchial brachytherapy for central lung tumors. A prospective, randomized comparison of two fractionation schedules.
R. Huber (1995)
Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer.
G. Kramer (2005)
Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study.
I. Mallick (2006)
The Superior Vena Cava Syndrome: Clinical Characteristics and Evolving Etiology
T. Rice (2006)
Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival.
T. de Vin (2014)
Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome.
J. Loeffler (1986)
The use of high dose rate endobronchial brachytherapy to palliate symptomatic recurrence of previously irriadiated lung cancer.
M. Kubaszewska (2008)
Radiothérapie du cancer bronchique non à petites cellules de stade III, inopérable, asymptomatique. Résultats définitifs d'un essai prospectif randomisé (240 patients)
M. Reinfuss (1999)
A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung.
P. Teo (1988)
Palliative radiotherapy regimens for non-small cell lung cancer.
J. Lester (2006)
Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.
R. Stevens (2015)
Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small-cell carcinoma of the bronchus.
S. Spiro (1983)
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).
A. Bezjak (2002)
Radiotherapy for malignant pleural mesothelioma.
E. Chapman (2006)
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
P. Iyengar (2014)
A reassessment of the clinical implications of the superior vena caval syndrome.
F. Ahmann (1984)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
Short-course palliative radiotherapy in non-small-cell lung cancer: results of a prospective study.
M. Lupattelli (2000)
An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.
A. Ashworth (2014)
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.
U. Pastorino (1997)
High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer.
L. F. Chang (1994)
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.
N. Bleehen (1992)
External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study.
H. Langendijk (2001)
Fraction size and dose parameters related to the incidence of pericardial effusions.
M. Martel (1998)
Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline
G. Rodrigues (2011)
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
S. Sundstrøm (2004)
Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules.
S. Erridge (2005)
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
P. Jenkins (2011)
Oligometastatic Non-Small-Cell Lung Cancer.
D. Palma (2015)
Palliative thoracic radiotherapy for lung cancer: a systematic review.
A. Fairchild (2008)
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
C. Collen (2014)
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
Neoadjuvant chemotherapy vs. radiotherapy alone for superior vena cava syndrome (SVCS) due to non-small cell lung cancer (NSCLC): preliminary results of randomized phase II trial
J. R. Pereira (1999)